MTRI Stock — InMed Pharmaceuticals Inc.

Up next

Q4 2021 earnings call transcript

Date not confirmed

Latest documents

what the company just published, in one sentence each

2026

Nov 10

Current report 8-K Events of Nov 6

Entered into a material agreement, Completed an acquisition or sale of assets, Financial results, Unregistered sale of equity, Change to shareholders' rights, Change in control, Director or officer change, or executive pay, Charter or bylaw amendment, or fiscal year change, Code of ethics change or waiver, Change in shell company status AI summary on its way

Nov 9

Current report 8-K

Merger closes with approximately $490 million financing

Mentari Therapeutics completed its merger with InMed Pharmaceuticals Inc. after raising approximately $490 million in gross proceeds; shares began trading on Nasdaq under MTRI on November 9, 2026.

Regulation FD disclosure

2 source passages

Mentari Therapeutics, Inc. (“Mentari” or the “Company”), a clinical-stage biotechnology company developing therapies for migraine prevention, today announced completion of the previously disclosed merger with InMed Pharmaceuticals Inc. (“InMed”). The combined company will operate under the name Mentari Therapeutics, Inc., and its shares will begin trading on the Nasdaq Capital Market today, November 9, 2026, under the name “Mentari Therapeutics, Inc.” and the ticker symbol “MTRI.” Immediately prior to the closing of the merger, Mentari completed previously announced private financings totaling approximately $490 million in gross proceeds Open the document at this passage

Nov 5

Current report 8-K Events of Nov 4

Shareholders approve proposals as name change and consolidation take effect

InMed Pharmaceuticals Inc., now Mentari Therapeutics, Inc., reported that shareholders approved all proposals on November 4, 2026, including Nevada redomestication. The company completed a one (1)-for-ten (10) share consolidation, reducing outstanding shares from 5,493,735 to approximately 549,374.

Regulation FD disclosure

5 source passages

Vancouver, British Columbia - November 4, 2026. InMed Pharmaceuticals Inc. (now Mentari Therapeutics, Inc.) (NASDAQ: INM) Each item of business voted on at the Meeting was approved by the shareholders. The approval of the Redomestication Proposal approved, via special resolution, the redomestication of the Company from British Columbia, Canada to the State of Nevada by continuation out of British Columbia under British Columbia law and domestication under Nevada law. The Company is also pleased to announce that, following the Meeting, it has completed the previously announced consolidation of its Common Shares on the basis of one (1) post-consolidation Common Share for each ten (10) pre-consolidation Common Shares (the "**Consolidation**"). As of November 4, 2026, immediately prior to the completion of the Consolidation, there were 5,493,735 Common Shares issued and outstanding in the capital of the Company. Following the completion of the Consolidation, there were approximately 549,374 Common Shares issued and outstanding. Open the document at this passage

Nov 5

Current report 8-K Events of Nov 4

Share consolidation precedes Nevada redomestication and merger

InMed Pharmaceuticals Inc. legally changed its name to Mentari Therapeutics, Inc. on November 4, 2026 and completed a one (1)-for-ten (10) common share consolidation. Shareholders approved merger-related issuance, redomestication to Nevada, and related proposals.

Charter or bylaw amendment, or fiscal year change, Shareholder vote results, Other events Read from the first part of this long document

4 source passages

On November 4, following the Shareholders Meeting, 2026, the Company filed a notice of alteration (the “Notice of Alteration”) with the Province of British Columbia Registrar of Companies to change the name of the Company from “InMed Pharmaceuticals Inc.” to “Mentari Therapeutics, Inc.,” effective as of November 4, 2026 (the “Name Change”). As of the effective time of the Consolidation, every ten (10) Common Shares issued and outstanding immediately prior to the Consolidation were automatically consolidated into one (1) issued and outstanding Common Share, without any change in shareholders’ proportionate equity or voting interests in the Company, other than as a result of the treatment of fractional shares described below. The Company’s shareholders approved (i) the issuance of the Common Shares, including the Common Shares issuable upon conversion of the Series A Preferred Shares, which will represent more than 20% of the Common Shares outstanding immediately prior to the First Merger, to stockholders of Mentari pursuant to the Merger Agreement, and (ii) the change of control of the Company resulting from the First Merger, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively. The Company’s shareholders approved, via special resolution, the redomestication of the Company from British Columbia, Canada to the State of Nevada by continuation out of British Columbia under British Columbia law and domestication under Nevada law. Open the document at this passage

Nov 3

Current report 8-K

Merger financing supports operations into 2029

InMed Pharmaceuticals Inc. expects its merger with Mentari Therapeutics to close in the fourth quarter of calendar 2026, supported by approximately US$490 million in financing intended to fund operations into 2029; Nasdaq granted until March 15, 2027 to regain equity compliance.

Regulation FD disclosure

4 source passages

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company") The proposed merger is expected to close in the fourth quarter of calendar 2026, subject to the satisfaction or waiver of the remaining closing conditions, including the required shareholder approvals. Mentari has announced private placements totaling approximately US$490 million in expected aggregate gross proceeds in connection with the transaction. This financing is expected to support operations into 2029, including through Phase 2a readouts for both of Mentari's lead PACAP-targeted programs. Nasdaq indicated that it had accepted the compliance plan, and determined that InMed has until March 15, 2027, to regain compliance with Nasdaq Listing Rule 5550(b)(1). Open the document at this passage

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 125 metrics

Revenue (TTM)

$4.51M

Trailing 12 months

Net income (TTM)

−$13.16M

Trailing 12 months

Revenue growth YoY

-26.2%

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+38.3%

Year over year · more shares

Price change (1Y)

—

Trailing year

Short interest

—

Latest settlement

View all 125 metrics

Quarterly results

Revenue Net income Net loss

▲13.4% $1.17M −$1.72M '24 Q3 ▼44.5% $1.28M −$1.94M '24 Q4* ▲40.2% $1.26M −$1.68M '25 Q1 ▼10.4% $1.11M −$2.58M '25 Q2 ▲7.6% $1.26M −$2.12M '25 Q3 ▲1.7% $1.30M $4.67M '25 Q4* ▼11.4% $1.12M −$1.73M '26 Q1 LATEST ▼26.2% $820,188 −$2.03M '26 Q2

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 18.7 · elevated Equity put/call 0.72

Technical

price trend

Strong Buy

50 / 200-day cross No cross

Price vs 200-day avg +50%

above

Price vs 50-day avg +30%

above

RSI (14) 60

neutral

MACD trend Positive

52-week position 99%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +38%

trailing

6-month return +7%

trailing

YTD return +73%

this year

Relative strength +5%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $14 › 200d $12 — 50d above 200d

Institutional flow Accumulating

6 of 20 funds reported for Sep 30 · net +1.3K sh shares · +1 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

0.01% of shares out · ▲ +1950.0% MoM · 1.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

20 holders — near 3-yr high, broad support

Fundamentals

Strong

Revenue growth +8%

Y/Y

Gross margin 35%

expanding

EPS growth +63%

Y/Y

Free cash flow $-8.6M

Quant / Vol

risk profile

Very High

Volatility 162%

annualized · 1-yr

Max drawdown −66%

past year

ATR 12.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy

0 · 3 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+50% Bullish

Price vs 50-day avg

+30% Bullish

RSI (14)

60 Neutral

MACD trend

Positive Bullish

52-week position

99% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $14 › 200d $12 — 50d above 200d

Institutional flow Accumulating

6 of 20 funds reported for Sep 30 · net +1.3K sh shares · +1 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

0.01% of shares out · ▲ +1950.0% MoM · 1.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

20 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $6 Now $18 · 99% Range high $19

vs 200-day avg +50% vs 50-day avg +30%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
MTRI InMed Pharmaceuticals Inc. this stock	$8.58M	—	+7.5%	—	1.2%
VRTX Vertex Pharmaceuticals Inc	$137.57B	+19.7%	+46.2%	34.9	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$98.40B	+23.2%	+20.8%	21.0	2.1%
MRNA Moderna, Inc.	$93.61B	+684.5%	+4.3%	—	8.2%
CSLLY Csl Ltd	$66.55B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

21

% held: 49.3%
Reported: 6 of 20
Top holder: ADAR1 Capital Management,…

Held Float

View

Short & Settlement

Short Interest Rising

Shares short

41

Days to cover: 1.0d
Change: +39 sh

View

Short Volume

Short vol %

10%

As of: Nov 12, 2026

Short Total

View

Financials

Revenue (FY)

$4.9M

Net income (FY): $-12.6M
EPS diluted: $-31.20

View

Filings

SEC Filings

Latest

8-K

Filed: Nov 10, 2026
This year: 27

View

Exempt Offerings

Offering

$6.0M

Filed: Dec 6, 2022

View

Earnings & Events

Webcasts

Last webcast

Jun 30, 2021

View

Investor Relations

	5D	20D	120D	MTD	YTD
MTRI	+38.9%	+38.0%	+6.7%	+14.7%	+73.1%
SPY	+3.3%	-1.9%	+1.5%	+0.2%	+11.0%
vs SPY	+35.6%	+39.9%	+5.2%	+14.5%	+62.1%

MTRI · InMed Pharmaceuticals Inc.

Price & Indicators

Up next

Latest documents

Metrics snapshot

Quarterly results

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance